Novo Nordisk's Pill Arithmetic: A 27% Profit Surge, a 5.9% Share Gain and the Price Test Still to Come

Novo Nordisk shares rose 5.9% on Wednesday after third-quarter 2026 results came in ahead of expectations, with a sharp jump in adjusted operating profit and the new Wegovy pill doing much of the heavy lifting. The Danish drugmaker also lifted its full-year guidance, a move Reuters identified as a further driver of the positive market reaction.

The headline number was striking. Adjusted operating profit climbed 27% at constant exchange rates to DKK 31,720 million — a gain that ran well ahead of the top line. Adjusted revenue rose 4% over the same period to DKK 79,195 million, of which the Wegovy pill contributed DKK 5.39 billion.

That gap between profit and sales growth is the detail worth dwelling on. The reported increase refers explicitly to adjusted operating profit measured at constant currencies, not to the unadjusted figure.

A pill that beat the consensus — and then some

Reuters put the pill's quarterly revenue at DKK 5.39 billion, a 53% advance on the prior quarter and comfortably above the DKK 4.62 billion analyst consensus. The momentum is real; whether it can be extrapolated is a separate question.

The broader Wegovy franchise offers the more telling scorecard. Sales of the injectable version fell 13% at constant currencies in the third quarter, yet the combined US Wegovy business grew 21% once the pill is included. In other words, the oral formulation did more than merely plug the gap left by the syringe.

Novo's own account suggests the pill is not simply cannibalising existing treatments. According to a BioSpace report published today, 80% of patients who started on the Wegovy pill had previously been untreated. Should that pattern hold, the oral form could open a growth path of its own rather than serving as a substitute. Obesity revenue across the division rose 22% at constant currencies to DKK 26.15 billion, showing the impulse reached the wider business.

Jefferies keeps its distance

Better numbers do not automatically translate into a more generous recommendation. Jefferies reiterated its "Hold" rating and DKK 275 price target today, noting that consensus forecasts still sit roughly 3 percentage points below the midpoint of the revised guidance. The broker flags a gap between market expectations and company projections without drawing a buy case from it — leaving any re-rating of estimates and the valuation of the stock as two distinct questions.

The US price reset hanging over 2027

The forward-looking puzzle is not volume but durability. From January 2027, Novo plans to cut US list prices for Wegovy by around 50% and for Ozempic by 35%. List prices are not the same as realised revenue, so the announced reduction does not imply a matching decline in sales. Still, the quality of growth moves centre stage: rising prescriptions alone would not prove that revenue and earnings can keep expanding.

Citi noted that the four-week average of Wegovy pill prescriptions was essentially flat in the week to 23 October. That is not evidence of a lasting stall, but it does temper what the strong quarterly performance can be taken to prove. A stagnating prescription trend would bite hardest if the injectable version keeps shedding revenue, since the pill would then have to absorb both the decline in the existing business and any price effects.

Regional assumptions add a further layer. According to Reuters, Novo's annual guidance assumes international revenue growth alongside a decline in the United States — the company's own planning does not presuppose a broad upswing across every market.

Competition and the next catalyst

The operating backdrop hardly offers an all-clear. Reuters reported just over a week ago that Eli Lilly's experimental retatrutide achieved better blood-sugar control than Ozempic in a diabetes study, with weight loss more than twice as high.

Two separate tests now sit before investors. The first is the expected FDA decision on CagriSema before the end of 2026, with Novo planning a US launch in early 2027 subject to a positive verdict — a potential widening of the product base that would not by itself guarantee commercial success. The second, and ultimately the more important, is whether Novo can convert additional demand into resilient revenue even under the planned lower prices. Today's figures provide a starting point, not a stress test.